Fundraising FoxBicara Therapeutics
NASDAQ: BCAXIncorporated in Delaware · 13 known investors
Find your way into Bicara Therapeutics
Sign up to see every warm intro you have to Bicara Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bicara Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors. The company's lead program, ficerafusp alfa, fuses an EGFR-directed antibody with a TGF-β ligand trap to simultaneously inhibit tumor cell growth and suppress immunosuppressive signaling in the tumor microenvironment, with initial development focused on head and neck squamous cell carcinoma.
Founders & leadership
Investors · 13
How we know: Aisling Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Eight Roads Ventures's portfolio page · Not right? Tell us
How we know: F-Prime Capital's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: Foresite Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: RA Capital's portfolio page · the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Red Tree Venture's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: Vedanta Capital's portfolio page · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · reuters.com · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeries CDec 2023Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Frequently asked questions
- What does Bicara Therapeutics do?
- Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors. The company's lead program, ficerafusp alfa, fuses an EGFR-directed antibody with a TGF-β ligand trap to simultaneously inhibit tumor cell growth and suppress immunosuppressive signaling in the tumor microenvironment, with initial development focused on head and neck squamous cell carcinoma.
- Who are Bicara Therapeutics's investors?
- Bicara Therapeutics's investors include Aisling Capital, Eight Roads Ventures, F-Prime Capital, Foresite Capital, Premji Invest, RA Capital, Red Tree Venture, Vedanta Capital and 5 more.